Találati lista | Tudóstér

001-es BibID:	BIBFORM073620
Első szerző:	Galimberti, Sara
Cím:	Vascular Endothelial Growth Factor Polymorphisms in Mantle Cell Lymphoma / Galimberti S., Nagy B., Palumbo G. A., Ciancia E., Buda G., Orciuolo E., Melosi A., Lambelet P., Ronca F., Petrini M.
Dátum:	2010
ISSN:	0001-5792
Megjegyzések:	In this study, we determined the allele and genotype frequencies of vascular endothelial growth factor (VEGF) G+405C, C-460T, C+936T and C-2578A single nucleotide polymorphisms (SNPs) in 32 patients affected by mantle cell lymphoma (MCL) and 58 healthy controls. Real-time PCR combined with melting curve analysis was used for the determination of SNP alleles. A significant difference in the allele frequency of VEGFC-460T and C+936T SNPs in MCL and healthy cases was not observed. On the contrary, VEGF G+405C and C-2578A SNP allele distribution was significantly lower in the patient group than among normal controls (p = 0.014, p = 0.001). This observation suggests that further investigation is warranted, both in vitro and in a larger series of patients, to further examine the role of VEGF polymorphisms in the pathogenesis of MCL. In addition, the use of quantitative real-time PCR combined with a melting curve analysis method in the detection of the 4 VEGF SNPs may have the potential to replace older and more time-consuming PCR-RFLP methods and bears further investigation.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban VEGF Mantle cell lymphoma
Megjelenés:	Acta Haematologica 123 : 2 (2010), p. 91-95. -
További szerzők:	Nagy Bálint (1956-) (molekuláris genetikus) Palumbo, Giuseppe Alberto Ciancia, Eugenio Buda, G. Orciuolo, E. Melosi, A. Lambelet, P. Ronca, F. Petrini, Mario
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM065230
Első szerző:	Galimberti, Sara
Cím:	Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphisms / Sara Galimberti, Balint Nagy, Eugenio Ciancia, Francesco Caracciolo, Edoardo Benedetti, Matteo Pelosini, Daniele Focosi, Mario Petrini
Dátum:	2010
ISSN:	1042-8194
Megjegyzések:	Notwithstanding the most recent and effectivetherapeutic strategies, in the majority of patientsmantle cell lymphoma (MCL) is still aggressive, withmedian overall survival (OS) ranging from 26 to 57months, when patients are stratified according to themantle cell lymphoma international prognostic index(MIPI) [1,2]. Thus, several immunochemotherapycombinations have been explored to improve outcome,such as R-Hyper-CVAD (rituximab plushyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, methotrexate, cytarabine)[2], R-CHOP (rituximab plus cyclophosphamide,doxorubicin, vincristine, prednisone) [3],maxi-CHOP [4], bortezomib plus R-CHOP [5],and mTOR (mammalian target of rapamycin)inhibitors [6]. Moreover, also autologous transplantstill remains a valid therapeutic option for youngpatients responsive to dose-intensified inductionchemotherapy, with 6-year overall survival andprogression-free survival of 70% and 66%, respectively[7].
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban mantle cell lymphoma VEGF Polymorphism
Megjelenés:	Leukemia & Lymphoma 52 : 1 (2010), p. 142-144. -
További szerzők:	Nagy Bálint (1956-) (molekuláris genetikus) Ciancia, Eugenio Caracciolo, Francesco Benedetti, Edoardo Pelosini, Matteo Focosi, Daniele Petrini, Mario
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: